dotlah! dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
Social Links
  • zedreviews.com
  • citi.io
  • aster.cloud
  • liwaiwai.com
  • guzz.co.uk
  • atinatin.com
0 Likes
0 Followers
0 Subscribers
dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
  • Lah!
  • Science

New Antibody Drug To Potentially Treat Cancer

  • August 5, 2019
Total
0
Shares
0
0
0

Singapore scientists and clinicians have discovered a promising use of antibodies to target a new cancer antigen, as an alternative for chemotherapy.

Scientists from A*STAR’s Institute of Molecular and Cell Biology (IMCB) have discovered an immunotherapy that could potentially be used to treat common cancers. They generated PRL3-zumab, a humanised antibody[1] to target the PRL-3 protein, a tumour antigen that promotes cancer growth and is found in about 80 per cent of 11 common cancers the researchers examined. Using antibodies to attack cancer cells in the body is a form of cancer immunotherapy that harnesses the immune system to kill cancer cells. By targeting the tumour specific antigen PRL-3; the PRL3-zumab humanised antibody could be used to develop targeted cancer treatments with advantages over chemotherapy and its disruptive side effects. It does so by not damaging surrounding healthy cells that do not express PRL-3. These findings were published in leading scientific journal Nature Communications on 6 June 2019.

Using animal models initially, the IMCB research team found that the PRL-3 mouse antibody could suppress tumour growths that expressed the PRL-3 antigen in gastric, liver, lung, ovary, breast, acute myeloid leukaemia (AML) and kidney cancers. Since 2012, the IMCB research team has been working in collaboration with clinician researchers from the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS); National University Hospital’s Tissue Repository (NUHS-TR); National Cancer Centre Singapore; Singapore General Hospital; Lee Kong Chian School of Medicine at Nanyang Technological University; Cancer Science Institute of Singapore, National University of Singapore; and Yong Loo Lin School of Medicine, National University of Singapore, to test the PRL3 protein expression on human tumour samples. The study could support PRL3-zumab as a first-in-class humanised antibody to be potentially used as a drug against a broad spectrum of tumours expressing PRL-3. These common cancers include those of the liver, lung, gastric, breast, colon, and kidney.

“PRL3-zumab represents an innovative and disruptive approach to cancer therapy, as it is highly targeted to cancer cells and has less side effects compared to traditional cancer drugs. It was conventionally perceived that antibodies cannot be used to target intracellular oncotargets due to their inability to cross cellular membranes. However, we discovered that the intracellular PRL3 oncotarget could be externalised on the surface of cancer cells to be targeted by antibodies to trigger the host’s immune system. This discovery opens a new avenue for cancer immunotherapy for a spectrum of intracellular oncotargets,” said Professor Qi Zeng, Research Director at A*STAR’s IMCB and lead researcher of the study.

A*ccelerate, A*STAR’s commercialisation arm, has patented Prof Qi Zeng’s concept globally since 2008. Prof Qi Zeng has also set up A*STAR spin-off Intra-ImmuSG Pte Ltd in 2015 to further develop PRL3-zumab for clinical use.

In 2018, PRL3-zumab completed Phase 1a and 1b clinical trials in solid tumours at the National University Cancer Institute, Singapore. Moving forward, the drug is also undergoing Phase 1b extension in liquid cancers (such as AML and multiple myeloma) at NCIS, monitored by Singapore Clinical Research Institute (SCRI). Furthermore, PRL3-zumab will soon be undergoing Phase 2 clinical trials at the National Cancer Centre Singapore (NCCS) to test the efficacy of PRL3-zumab against broader types of solid tumours. Phase 1 evaluates the safety and tolerability of PRL3-zumab in advanced solid tumours patients, while Phase 2 will test for efficacy and proof of concept of the therapy.


For more information, please refer to the paper “PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein”, published online by the journal Nature Communications on 6 June 2019.

Link to paper: https://www.nature.com/articles/s41467-019-10127-x

 

[1] Antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans.

Total
0
Shares
Share
Tweet
Share
Share
Related Topics
  • Cancer
  • Cancer Theraphy
  • Research
majulah

Previous Article
  • Lah!

Sembcorp And Cache Logistics Trust Celebrate Completion Of 8.0 Megawatt-Peak Rooftop Solar Power Project

  • August 5, 2019
View Post
Next Article
  • Lah!

An NDP Show That Celebrates Our Values And Inspires Singaporeans

  • August 5, 2019
View Post
You May Also Like
View Post
  • Lah!

Tariffs, Trump, and Other Things That Start With T – They’re Not The Problem, It’s How We Use Them

  • John Francis
  • March 25, 2025
View Post
  • Lah!

Canonical announces 12 year Kubernetes LTS

  • John Francis
  • March 4, 2025
dotlah-smartnation-singapore-lawrence-wong
View Post
  • Artificial Intelligence
  • Featured
  • Features
  • Lah!
  • Machine Learning
  • Technology

Growth, community and trust the ‘building blocks’ as Singapore refreshes Smart Nation strategies: PM Wong

  • Dean Marc
  • October 9, 2024
dotlah-singapore-ndp-2024
View Post
  • Lah!

Here’s what to expect for NDP 2024!

  • dotlah.com
  • August 9, 2024
dotlah-singapore-airlines_may_21-1716298816
View Post
  • Lah!

Severe turbulence during Singapore Airlines flight leaves several people badly injured. One man died

  • majulah
  • May 22, 2024
dotlah-pm-lee-lawrence-wong-9656d4cd-1fa4-40ed-905d-e19e639b8476_728802dd
View Post
  • Lah!
  • People
  • Politics

End of Lee Era for Singapore as PM Steps Down

  • dotlah.com
  • May 16, 2024
DPM Lawrence Wong will be Singapore's fourth prime minister on May 15. ST PHOTO: LIM YAOHUI
View Post
  • Lah!
  • People
  • Politics

7 things to know about Singapore’s next prime minister Lawrence Wong

  • dotlah.com
  • May 15, 2024
When asked about his leadership style, DPM Lawrence Wong said he will be open and consultative, but he will not shirk from doing what is necessary for Singapore's future. ST PHOTO: LIM YAOHUI
View Post
  • Features
  • Lah!
  • People
  • Politics

‘We are prepared to relook everything’: Lawrence Wong on a changing society and his hopes for S’pore

  • dotlah.com
  • May 15, 2024


Trending
  • 1
    • People
    • World Events
    How Contagious Is The Wuhan Coronavirus And Can You Spread It Before Symptoms Start?
    • January 30, 2020
  • 2
    • Technology
    Making The Quantum Leap In Computing
    • February 4, 2020
  • 3
    • Cities
    • Technology
    Unlocking Technology For The Global Goals
    • January 22, 2020
  • 4
    • People
    How Does The Coronavirus Affect Different Age Groups?
    • March 23, 2020
  • 5
    • Technology
    PUB Seeks To Boost Rainfall Forecasting Capabilities With Radar Technology
    • January 27, 2020
  • 6
    • Science
    • Technology
    One-Hour Antibody Test Tracks Neutralising Antibodies Of COVID-19
    • May 19, 2020
  • 7
    • Technology
    Big Tech Antitrust Hearings, A NOT Wallstreet Or Mainstreet Viewpoint
    • August 3, 2020
  • 8
    • People
    The Most Populous Nations On Earth
    • July 29, 2020
  • Kitchen Knives - Best All-Around Picks in 2025 9
    • Gears
    Kitchen Knives : The Surgeons of Cooking – Best All-Around Picks in 2025
    • September 15, 2025
  • 10
    • Cities
    Opportunities Aplenty For ASEAN Members In Building Smart Cities
    • August 14, 2019
  • 11
    • Cities
    • Lah!
    SGX Named Commodity Exchange Of The Year At Energy Risk Awards
    • September 24, 2021
  • 12
    • People
    • Technology
    Oppenheimer: July 28 Panel Discussion Focuses On The Man Behind The Movie
    • July 19, 2023
Trending
  • Kitchen Knives - Best All-Around Picks in 2025 1
    Kitchen Knives : The Surgeons of Cooking – Best All-Around Picks in 2025
    • September 15, 2025
  • 2
    Apple unveils iPhone 17 Pro and iPhone 17 Pro Max, the most powerful and advanced Pro models ever
    • September 9, 2025
  • 3
    Apple debuts iPhone 17
    • September 9, 2025
  • Fruits and vegetables for cooking. For food processors. 4
    Food Processor: The Swiss Army Knife of the Kitchen – Best All-Around Picks in 2025
    • September 8, 2025
  • 5
    Meet Samsung Galaxy Tab S11 Series: Packing Everything You Expect From a Premium Tablet
    • September 4, 2025
  • 6
    Malaysia’s ‘ASEAN Shenzhen’ needs some significant legal reform to take off — here’s how
    • August 25, 2025
  • French Fries 7
    Air Fryer: The One Cooking Appliance to Rule Them All – Best All-Around Picks in 2025
    • August 22, 2025
  • 8
    Samsung Electronics Debuts Odyssey G7 Monitors, Showcasing Top Games on Its Displays at Gamescom 2025
    • August 20, 2025
  • 9
    HP Cranks Up the Game with Smarter Systems, Cooler Builds, and Gear That Hits Different
    • August 14, 2025
  • 10
    New Trump tariffs: early modelling shows most economies lose – the US more than many
    • August 6, 2025
Social Links
dotlah! dotlah!
  • Cities
  • Technology
  • Business
  • Politics
  • Society
  • Science
  • About
Connecting Dots Across Asia's Tech and Urban Landscape

Input your search keywords and press Enter.